Journal of drug targeting,
Journal Year:
2024,
Volume and Issue:
32(7), P. 770 - 784
Published: May 8, 2024
The
World
Health
Organization
(WHO)
reported
that
of
all
the
non-communicable
diseases,
cancer
is
considered
second
cause
death
worldwide.
This
has
driven
big
pharma
companies
to
prioritize
anticancer
products
in
their
pipeline.
In
addition,
research
focused
on
exploration
new
molecules
and
design
suitable
dosage
forms
achieve
effective
drug
delivery
tumor
site.
Nanotechnology
a
valuable
tool
build
nano
systems
with
controlled
targeted
release
properties.
Nanoparticles
can
be
fabricated
by
robust,
scalable
economic
techniques
using
various
polymers.
Moreover,
specific
functional
groups
introduced
surface
nanoparticles
enabling
targeting
tissue;
besides,
they
exhibit
versatile
patterns
according
rate
polymer
degradation.
review
outlines
processes
advances
functionalization
employed
for
treatment
breast
cancer.
therapeutic
molecules,
polymers
used
fabricate
nanoparticles,
prepare
have
been
reviewed
focus
functionalize
these
ligands
target
different
types
ACS Nano,
Journal Year:
2020,
Volume and Issue:
14(10), P. 12281 - 12290
Published: Oct. 6, 2020
The
three
design
criteria
of
anticancer
nanomedicines
to
improve
efficacy
and
reduce
toxicity
have
been
debated
for
decades:
(1)
Nanomedicines
increase
drug
accumulation
through
enhanced
permeability
retention
(EPR)
in
tumors
efficacy.
(2)
Long
systemic
circulation
with
high
plasma
concentration
reduces
reticuloendothelial
system
(RES)
clearance
decreases
the
normal
organs
toxicity,
enhance
EPR
effect.
(3)
A
universal
nanodelivery
platform
based
on
long
can
be
developed
deliver
different
drugs.
Although
these
repeatedly
confirmed
preclinical
xenograft
cancers,
majority
failed
clinical
efficacy,
while
efficacies/safety
successful
are
inconsistent
criteria.
First,
debate
over
tumor
may
mixed
two
questions
missed
more
clinically
relevant
comparisons
versus
free
When
compared
tissues,
has
both
mouse
human
cancers.
However,
not
drugs,
despite
outstanding
improvement
Heterogeneity
cancers
occurs
small/large
molecules
nanomedicines,
which
cannot
fully
explain
poor
translation
nanomedicines'
from
cancer
models
patients.
Second,
long-circulation
nanomedicine
should
used
as
a
criterion
because
it
does
further
by
patients
nor
universally
distribution
organs.
In
contrast,
change
tissue
alter
efficacy/safety.
Third,
that
uses
same
drugs
is
feasible.
Rather,
drug-specific
systems
required
overcome
intrinsic
shortcomings
delivered
determined
physicochemical,
pharmacokinetic,
pharmacodynamic
properties
nanocarriers
their
Nano Convergence,
Journal Year:
2021,
Volume and Issue:
8(1)
Published: Nov. 2, 2021
Modern
medicine
has
been
waging
a
war
on
cancer
for
nearly
century
with
no
tangible
end
in
sight.
Cancer
treatments
have
significantly
progressed,
but
the
need
to
increase
specificity
and
decrease
systemic
toxicities
remains.
Early
diagnosis
holds
key
improving
prognostic
outlook
patient
quality
of
life,
diagnostic
tools
are
cusp
technological
revolution.
Nanotechnology
steadily
expanded
into
reaches
chemotherapy,
radiotherapy,
diagnostics,
imaging,
demonstrating
capacity
augment
each
advance
care.
Nanomaterials
provide
an
abundance
versatility,
functionality,
applications
engineer
specifically
targeted
medicine,
accurate
early-detection
devices,
robust
imaging
modalities,
enhanced
radiotherapy
adjuvants.
This
review
provides
insights
current
clinical
pre-clinical
nanotechnological
drug
therapy,
radiation
therapy.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: July 5, 2024
Abstract
Cancer
stem
cells
(CSCs),
a
small
subset
of
in
tumors
that
are
characterized
by
self-renewal
and
continuous
proliferation,
lead
to
tumorigenesis,
metastasis,
maintain
tumor
heterogeneity.
continues
be
significant
global
disease
burden.
In
the
past,
surgery,
radiotherapy,
chemotherapy
were
main
cancer
treatments.
The
technology
treatments
develop
advance,
emergence
targeted
therapy,
immunotherapy
provides
more
options
for
patients
certain
extent.
However,
limitations
efficacy
treatment
resistance
still
inevitable.
Our
review
begins
with
brief
introduction
historical
discoveries,
original
hypotheses,
pathways
regulate
CSCs,
such
as
WNT/β-Catenin,
hedgehog,
Notch,
NF-κB,
JAK/STAT,
TGF-β,
PI3K/AKT,
PPAR
pathway,
their
crosstalk.
We
focus
on
role
CSCs
various
therapeutic
outcomes
resistance,
including
how
affect
content
alteration
related
molecules,
CSCs-mediated
clinical
value
targeting
refractory,
progressed
or
advanced
tumors.
summary,
efficacy,
method
is
difficult
determine.
Clarifying
regulatory
mechanisms
biomarkers
currently
mainstream
idea.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(4), P. 3188 - 3188
Published: Feb. 6, 2023
Biopolymeric
nanoparticles
are
gaining
importance
as
nanocarriers
for
various
biomedical
applications,
enabling
long-term
and
controlled
release
at
the
target
site.
Since
they
promising
delivery
systems
therapeutic
agents
offer
advantageous
properties
such
biodegradability,
biocompatibility,
non-toxicity,
stability
compared
to
toxic
metal
nanoparticles,
we
decided
provide
an
overview
on
this
topic.
Therefore,
review
focuses
use
of
biopolymeric
animal,
plant,
algal,
fungal,
bacterial
origin
a
sustainable
material
potential
drug
systems.
A
particular
focus
is
encapsulation
many
different
categorized
bioactive
compounds,
drugs,
antibiotics,
other
antimicrobial
agents,
extracts,
essential
oils
into
protein-
polysaccharide-based
nanocarriers.
These
show
benefits
human
health,
especially
successful
anticancer
activity.
The
article,
divided
protein-based
further
according
biopolymer,
enables
reader
select
appropriate
more
easily
incorporation
desired
component.
latest
research
results
from
last
five
years
in
field
production
loaded
with
healthcare
applications
included
review.
Journal of Personalized Medicine,
Journal Year:
2024,
Volume and Issue:
14(7), P. 723 - 723
Published: July 4, 2024
Breast
cancer
remains
the
most
prevalent
among
women
worldwide,
driving
urgent
need
for
innovative
approaches
to
diagnosis
and
treatment.
This
review
highlights
pivotal
role
of
nanoparticles
in
revolutionizing
breast
management
through
advancements
interconnected
including
targeted
therapy,
imaging,
personalized
medicine.
Nanoparticles,
with
their
unique
physicochemical
properties,
have
shown
significant
promise
addressing
current
treatment
limitations
such
as
drug
resistance
nonspecific
systemic
distribution.
Applications
range
from
enhancing
delivery
systems
sustained
release
developing
diagnostic
tools
early
precise
detection
metastases.
Moreover,
integration
into
photothermal
therapy
synergistic
use
existing
treatments,
immunotherapy,
illustrate
transformative
potential
care.
However,
journey
towards
clinical
adoption
is
fraught
challenges,
chemical
feasibility,
biodistribution,
efficacy,
safety
concerns,
scalability,
regulatory
hurdles.
delves
state
nanoparticle
research,
applications
diagnosis,
obstacles
that
must
be
overcome
integration.
ACS Nano,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 17, 2025
Since
their
inception
in
the
early
1960s,
development
and
use
of
nanoscale
materials
have
progressed
tremendously,
roles
diverse
fields
ranging
from
human
health
to
energy
electronics
are
undeniable.
The
application
nanotechnology
inventions
has
revolutionized
many
aspects
everyday
life
including
various
medical
applications
specifically
drug
delivery
systems,
maximizing
therapeutic
efficacy
contained
drugs
by
means
bioavailability
enhancement
or
minimization
adverse
effects.
In
this
review,
we
utilize
CAS
Content
Collection,
a
vast
repository
scientific
information
extracted
journal
patent
publications,
analyze
trends
nanoscience
research
relevant
an
effort
provide
comprehensive
detailed
picture
field.
We
examine
publication
landscape
area
insights
into
current
knowledge
advances
developments.
review
major
classes
nanosized
routes,
targeted
diseases.
outline
most
discussed
concepts
assess
advantages
nanocarriers.
objective
is
broad
overview
evolving
regarding
challenges,
evaluate
growth
opportunities.
merit
stems
extensive,
wide-ranging
coverage
up-to-date
information,
allowing
unmatched
breadth
analysis
in-depth
insights.
Plants,
Journal Year:
2021,
Volume and Issue:
10(3), P. 569 - 569
Published: March 17, 2021
Taxanes,
mainly
paclitaxel
and
docetaxel,
the
microtubule
stabilizers,
have
been
well
known
for
being
first-line
therapy
breast
cancer
more
than
last
thirty
years.
Moreover,
they
also
used
treatment
of
ovarian,
hormone-refractory
prostate,
head
neck,
non-small
cell
lung
carcinomas.
Even
though
docetaxel
significantly
enhance
overall
survival
rate
patients,
there
are
some
limitations
their
use,
such
as
very
poor
water
solubility
occurrence
severe
side
effects.
However,
this
is
what
pushes
research
on
these
microtubule-stabilizing
agents
further
yields
novel
taxane
derivatives
with
improved
properties.
Therefore,
review
article
brings
recent
advances
reported
in
two
We
focused
especially
methods
isolation,
mechanism
action,
development
derivatives,
formulations,
tumor-targeted
drug
delivery.
Since
chemoresistance
can
be
an
unsurpassable
hurdle
administration,
a
significant
part
has
devoted
to
combination
taxanes
treatment.
Last
but
not
least,
we
summarize
ongoing
clinical
trials
compounds
bring
perspective
advancements
field.
